PAOG - New Independent CBD Research Appears To Support PAOG RespRx Research
highlighted an article just released from Life Sciences:
CBD could reduce lung damage caused by COVID-19
On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.
The Life Sciences article reports:
"One way CBD appears to reduce the "cytokine storm" that damages the lungs and kills many patients with COVID-19 is by enabling an increase in levels of a natural peptide called apelin, which is known to reduce inflammation and whose levels are dramatically reduced in the face of this storm."
"They reported this summer in the journal Cannabis and Cannabinoid Research that treatment with CBD reduced excessive lung inflammation, enabling improvements in lung function, healthier oxygen levels, and repair of some of the structural damage to the lungs that are classic with [adult respiratory distress syndrome] ARDS. The investigators said then more work was needed, including finding how CBD produced the significant changes as well as human trials, before it should be included as part of a treatment regimen for COVID-19."
Earlier today, PAOG announced the company plans to release a new key update this Friday, October 23, 2020, on its progress to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG announced last week that it anticipates soon entering into an agreement with a contract research organization (CRO) making a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval.
www.paogroupinc.com
News 
Market Data 
Discover 
